

NEW ZEALAND DATA SHEET

1 PRODUCT NAME

SUBOXONE® FILM 2 mg/0.5 mg soluble film

SUBOXONE® FILM 4 mg/1 mg soluble film

SUBOXONE® FILM 8 mg/2 mg soluble film

SUBOXONE® FILM 12 mg/3 mg soluble film

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUBOXONE FILM is available in four dosage strengths:

2 mg buprenorphine (as hydrochloride) + 0.5 mg naloxone (as hydrochloride dihydrate)

4 mg buprenorphine (as hydrochloride) + 1 mg naloxone (as hydrochloride dihydrate)

8 mg buprenorphine (as hydrochloride) + 2 mg naloxone (as hydrochloride dihydrate) and

12 mg buprenorphine (as hydrochloride) + 3 mg naloxone (as hydrochloride dihydrate).

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

SUBOXONE FILM is a soluble film intended for sublingual and or buccal administration only.

SUBOXONE FILM is supplied as an orange rectangular soluble film with a white printed logo in four dosage strengths:

- “N2” for 2/0.5 mg buprenorphine/naloxone
- “N4” for 4/1 mg buprenorphine/naloxone*
- “N8” for 8/2 mg buprenorphine/naloxone and
- “N12” for 12/3 mg buprenorphine/naloxone*.

* Not supplied

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Treatment of opioid dependence within a framework of medical, social and psychological treatment.

4.2 DOSE AND METHOD OF ADMINISTRATION

Treatment with SUBOXONE FILM is intended for adults and children aged 16 years or over who have agreed to be treated for opioid dependence.

SUBOXONE FILM and SUBOXONE TABLET do not meet all criteria for bioequivalence (see section 5.2 Pharmacokinetic Properties). Patients being switched between tablets and soluble films may therefore require dosage adjustment.

The routes of administration of SUBOXONE FILM is sublingual and buccal only. The film formulation is not designed to be split or broken.

SUBOXONE FILMS should not be swallowed whole as this reduces the bioavailability of the medicine. Physicians must advise patients that the sublingual and buccal route are the only effective and safe route of administration for this medicine.

Please note: The following instructions refer to the buprenorphine content of each dose.

Method of Administration

Sublingual Administration

Place one film under the tongue, close to the base on the left or right side. If an additional film is necessary to achieve the prescribed dose, place an additional film sublingually on the opposite side from the first film. Place the film in a manner to minimize overlapping as much as possible. The film must be kept under the tongue until the film is completely dissolved. If a third film is necessary to achieve the prescribed dose, place it under the tongue on either side after the first 2 films have dissolved.

Buccal Administration

Place one film on the inside of the right or left cheek. If an additional film is necessary to achieve the prescribed dose, place an additional film on the inside of the opposite cheek. The film must be kept on the inside of the cheek until the film is completely dissolved. If a third film is necessary to achieve the prescribed dose, place it on the inside of the right or left cheek after the first two films have dissolved.

No food or drink should be consumed until the film is completely dissolved. SUBOXONE FILM should NOT be chewed, swallowed, or moved from placement.

Starting SUBOXONE FILM

An adequate maintenance dose, titrated to clinical effectiveness, should be achieved as rapidly as possible to prevent undue opioid withdrawal symptoms due to inadequate dosage.

Prior to induction, consideration should be given to the type of opioid dependence (i.e. long- or short-acting opioid), the time since last opioid use and the degree or level of opioid dependence.

Due to naloxone exposure being somewhat higher following buccal administration than sublingual administration, it is recommended that the sublingual site of administration be used during induction to minimise naloxone exposure and to reduce the risk of precipitated withdrawal.

Induction onto SUBUTEX (buprenorphine tablets) is recommended when there is doubt about the level of dependence or previous opioid use, to avoid precipitating opioid withdrawal. Patients can be switched to SUBOXONE FILM on the third day.

When initiating buprenorphine treatment, the physician should be aware of the partial agonist profile of the molecule to the μ opioid receptors, which can precipitate withdrawal in opioid-dependent patients if given too soon after the administration of heroin, methadone or another opioid. To avoid precipitating withdrawal, induction with buprenorphine should be undertaken when objective and clear signs of withdrawal are evident.

Patients taking Heroin (or Other Short-acting Opioids)

When treatment starts the dose of SUBOXONE FILM should be taken at least 6 hours after the patient last used opioids and when the objective signs of withdrawal appear. The Clinical Opiate Withdrawal Scale (COWS) may be a useful reference assessment however clinical assessment of withdrawal symptoms with consideration of the patient's baseline presentation is important, particularly for patients in mild withdrawal (COWS score of 5-12). The recommended starting dose is 4-8 mg SUBOXONE FILM on Day One, with a possible additional 4 mg depending on the individual patient's requirement. The suggested target total dose for Day One is in the range of 8-12 mg SUBOXONE FILM. For patients with moderate or severe withdrawal at the time of the first dose, an initial dose of 8 mg may be appropriate with an additional 4 mg depending on the individual patient's requirement to a total maximum of 12 mg on Day 1.

Lower doses (e.g. 2 or 4 mg total on Day 1) are suited to those with low or uncertain levels of opioid dependence, with high risk polydrug use (alcohol, benzodiazepines) or with other severe medical complications. Seek specialist advice if concerned.

Patients on Methadone

Before starting treatment with SUBOXONE FILM, the maintenance dose of methadone should be reduced to the minimum methadone daily dose that the patient can tolerate. The first dose of SUBOXONE FILM should be taken at least 24 hours after the patient last used methadone. An initial dose of 2 mg SUBOXONE FILM may be administered when moderate withdrawal is apparent (COWS \geq 13). An additional dose of 6 mg SUBOXONE FILM can be administered one hour later if the initial dose does not precipitate withdrawal. Supplementary doses can be administered every 1 to 3 hours according to withdrawal severity:

- 0 mg if there is no or minimal withdrawal (COWS < 5);
- 4 mg if there is mild withdrawal (COWS 5-12);
- 8 mg if there is moderate to severe withdrawal (COWS \geq 13).

The suggested target total dose for Day One is in the range of 8 – 16 mg SUBOXONE FILM. A maximum daily dose of 32 mg should not be exceeded.

During the initiation of treatment, patients need frequent monitoring. SUBOXONE FILM should be dispensed in multiple doses over the first 4 to 6 hours of the transfer. Dosing supervision is recommended to ensure proper placement of the dose and to observe patient response to treatment as a guide to effective dose titration according to clinical effect.

Switching between treatments for opioid dependence

Patients should be closely monitored during the switching period from buprenorphine or methadone to buprenorphine/naloxone since withdrawal symptoms have been reported.

Switching between SUBOXONE FILM strengths

The sizes and the compositions of the four units of SUBOXONE FILMs, i.e. 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg and the 12 mg/3 mg units are different from one another. If patients switch between various combinations of lower and higher strength units of SUBOXONE FILMs to obtain the same total dose, (e.g. from three 4 mg/1 mg units to a single 12 mg/3 mg unit, or vice-versa), systemic exposures of buprenorphine and naloxone may be different and patients should be monitored for over-dosing or under-dosing. For this reason, pharmacist should not substitute one or more film strengths for another without approval of the prescriber.

Switching between sublingual and buccal sites of administration

The systemic exposure of buprenorphine between buccal and sublingual administration of SUBOXONE FILM is similar. Therefore, once induction is complete, patients can switch between buccal and sublingual administration without significant risk of under or overdosing.

Dose adjustment in hepatic impairment

Use of SUBOXONE FILM is contraindicated in patients with severe hepatic impairment.

SUBOXONE FILM may not be appropriate for patients with moderate hepatic impairment. SUBOXONE FILM may be used with caution for maintenance treatment in patients with moderate hepatic impairment, who have initiated treatment on a buprenorphine-only product. Patients with moderate hepatic impairment prescribed SUBOXONE should be monitored for signs and symptoms of precipitated opioid withdrawal. In addition, lower initial doses and cautious titration of dosage may be required in patients with moderate hepatic impairment.

No dosage adjustment is needed in patients with mild hepatic impairment.

Dosage Adjustment and Maintenance

The dose of SUBOXONE FILM should be adjusted progressively according to the clinical effect in the individual patient. The dosage is adjusted in increments or decrements of 2 – 8 mg

buprenorphine to a level that maintains the patient in treatment and suppresses opioid withdrawal effects according to reassessments of the clinical and psychological status of the patient.

Most patients require daily buprenorphine doses in the range 12-24 mg to achieve stabilisation, although some patients require higher (e.g. up to 32 mg/day) or lower (4-8 mg/day) doses to achieve their treatment goals. During maintenance therapy, it may be necessary to periodically restabilise patients to new maintenance doses in response to changing patient needs.

Less than daily dosing

After a satisfactory period of stabilisation has been achieved, the frequency of dosing may be decreased to dosing every other day at twice the individually titrated daily dose. For example, a patient stabilised to receive a daily dose of 8 mg may be given 16 mg on alternate days, with no medication on the intervening days. However, the dose given on any one day should not exceed 32 mg.

In some patients, after a satisfactory period of stabilisation has been achieved, the frequency of dosing may be decreased to 3 times a week (for example on Monday, Wednesday and Friday). The dose on Monday and Wednesday should be twice the individually titrated daily dose and the dose on Friday should be three times the individually titrated daily dose, with no medication on the intervening days. However, the dose given on any one day should not exceed 32 mg.

The patient should be observed following the first multi-dose administration to initiate the less-than-daily dosing regimen and whenever treated with high doses. Patients who sporadically use concomitant CNS-active medications or substances should be monitored closely.

Reducing Dosage and Stopping Treatment

The decision to discontinue therapy with SUBOXONE FILM should be made as part of a comprehensive treatment plan. A possible gradual dose taper over a period of 21 days is shown in Table 1.

Table 1.	Gradual dose taper schedule		
Week	20 mg Maintenance dose	16 mg Maintenance dose	8 mg Maintenance dose
1	16 mg	12 mg	8 mg
2	8 mg	8 mg	4 mg
3	4 mg	4 mg	4 mg

4.3 CONTRAINDICATIONS

Hypersensitivity to buprenorphine or naloxone or any other component of the soluble film.

Children less than 16 years of age.

Severe respiratory or hepatic insufficiency (Child-Pugh C).

Acute intoxication with alcohol or other CNS depressant.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

General

SUBOXONE FILM should be administered with caution in debilitated patients and those with impairment of hepatic, pulmonary, or renal function; myxoedema or hypothyroidism, adrenal cortical insufficiency (e.g. Addison's disease); CNS depression or coma; toxic psychoses; acute alcoholism; or delirium tremens.

Buprenorphine increases intracholedochal pressure as do other opioids. Therefore, caution should be exercised when SUBOXONE FILM is to be administered to patients with dysfunction of the biliary tract.

As with other opioids, caution is advised in patients using buprenorphine and having hypotension, prostatic hypertrophy or urethral stenosis.

Opioids may produce orthostatic hypotension in ambulatory patients.

As with other mu-opioid receptor agonists, the administration of SUBOXONE FILM may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

Use in the elderly

The safety and efficacy of buprenorphine in elderly patients over 65 years have not been established.

Misuse, abuse and diversion

SUBOXONE can be misused or abused in a manner similar to other opioids, legal or illicit. Some risks of misuse and abuse include overdose, spread of blood borne viral infections, respiratory depression and hepatic injury. SUBOXONE misuse by someone other than the intended patient poses the additional risk of new opioid dependent individuals using buprenorphine as the primary opioid of abuse and may occur if the medicine is distributed for illicit use directly by the intended patient or if the medicine is not safeguarded against theft, including in the home. Sub-optimal treatment with SUBOXONE may prompt medication misuse by the patient, leading to overdose or treatment dropout. A patient who is under-dosed with SUBOXONE may continue responding to uncontrolled withdrawal symptoms by self-medicating with opioids, alcohol or other sedative-hypnotics such as benzodiazepines. To minimise risk of misuse, abuse or diversion, appropriate precautions should be taken when prescribing and dispensing SUBOXONE, such as to avoid prescribing multiple refills early in treatment and to conduct patient follow-up visits with clinical monitoring that is appropriate to the patient's level of stability.

Patients dependent upon concomitant CNS-active substances, including alcohol, should not be treated with the increased doses required by the less-than-daily dosing regimen intended for use in a supervised dose setting. Patients with sporadic use of concomitant non-opioid medications should be monitored closely and all patients dosed on a less-than-daily basis should be observed following the first multi-dose administration when initiating less-than-daily dosing or whenever treated with high doses.

Respiratory Depression

SUBOXONE FILM is intended for sublingual or buccal use only. Significant respiratory depression has been associated with buprenorphine, particularly by the intravenous route. A number of deaths have occurred when buprenorphine was used in combination with benzodiazepines, in opioid naïve individuals, or when buprenorphine was otherwise not used according to prescribing information. Deaths have also been reported in association with concomitant administration of buprenorphine with other depressants such as alcohol or other opioids. Patients should be warned of the potential danger of the self-administration of benzodiazepines or other CNS depressants at the same time as receiving SUBOXONE FILM.

In the event of depression of respiratory or cardiac function, see section 4.9 Overdose.

SUBOXONE FILM should be used with caution in patients with compromised respiratory function (e.g. chronic obstructive pulmonary disease, asthma, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, pre-existing respiratory depression or kyphoscoliosis).

SUBOXONE FILM may cause severe, possible fatal, respiratory depression in children who accidentally ingest it. Protect children against exposure.

CNS Depression

SUBOXONE may cause drowsiness, particularly when used together with alcohol or other central nervous system depressants (such as benzodiazepines, tranquilisers, sedatives or hypnotics (see section 4.5 Interactions)). When such combined therapy is contemplated, reduction of the dose of one or both agents should be considered. SUBOXONE FILM should be used cautiously with MAOIs,

based on experience with morphine.

Hepatitis, Hepatic Events

Cases of acute hepatic injury have been reported in opioid-dependent patients, both in clinical trials and post marketing adverse reaction reports. The spectrum of abnormalities ranges from transient asymptomatic elevations in hepatic transaminases to case reports of cytolytic hepatitis, hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic encephalopathy and death. Serious cases of acute hepatic injury have also been reported in a context of misuse, especially by the intravenous route. These hepatic injuries were dose-related and could be due to mitochondrial toxicity. Pre-existing or acquired mitochondrial impairment (genetic diseases, viral infections particularly chronic hepatitis C, liver enzyme abnormalities, alcohol abuse, anorexia, associated mitochondrial toxins, e.g. aspirin, isoniazid, valproate, amiodarone, antiviral nucleoside analogues, or drug misuse by injection) could promote the occurrence of such hepatic injuries. These co-factors must be taken into account before prescribing SUBOXONE FILM and during treatment monitoring. Baseline liver function tests and documentation of viral hepatitis status are recommended prior to commencing therapy. Patients who are positive for viral hepatitis, on concomitant medicines (see section 4.5 Interactions) and/or have existing liver dysfunction are at greater risk of liver injury. Regular monitoring of liver function is recommended. A biological and etiological evaluation is recommended when a hepatic event is suspected. Depending upon the findings, the medicine may be discontinued cautiously so as to prevent withdrawal syndrome and to prevent a return to opioid dependence. If treatment is continued, hepatic function should be monitored closely.

Use in hepatic Impairment

Buprenorphine and naloxone are extensively metabolised by the liver. The effects of hepatic impairment on the pharmacokinetics of buprenorphine and naloxone were evaluated in a post-marketing study, in which a SUBOXONE 2.0/0.5 mg (buprenorphine/naloxone) sublingual tablet was administered to healthy subjects and subjects with varying degrees of hepatic impairment. Plasma levels were found to be elevated for buprenorphine and naloxone in patients with moderate to severe hepatic impairment (Table 2). Patients with severe hepatic impairment experienced substantially greater increases in exposure to naloxone relative to buprenorphine and patients with moderate hepatic impairment experienced greater increases in exposure to naloxone relative to buprenorphine. The clinical impact in terms of efficacy/safety is unknown but is likely to be greater for those with severe hepatic impairment than those with moderate hepatic impairment.

The doses of buprenorphine and naloxone in SUBOXONE cannot be individually titrated. As such, SUBOXONE should be avoided in patients with severe hepatic impairment. Use of SUBOXONE may not be appropriate in those with moderate hepatic impairment. It may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine-only product. Patients with moderate hepatic impairment should be monitored for signs and symptoms of precipitated opioid withdrawal. In addition, lower initial doses and cautious titration of dosage may be required in patients with moderate hepatic impairment. As with all patients treated with SUBOXONE, liver function tests should be monitored prior to and during treatment. See also section 4.2 Dose and Method of administration.

Table 2: Effect of hepatic impairment on pharmacokinetic parameters of buprenorphine and naloxone following buprenorphine/naloxone administration (change relative to healthy subjects)

PK parameter	Mild Hepatic Impairment (Child-Pugh Class A) (n=9)	Moderate Hepatic Impairment (Child-Pugh Class B) (n=8)	Severe Hepatic Impairment (Child-Pugh Class C) (n=8)
BUPRENORPHINE			
C _{max}	1.2 fold increase	1.1 fold increase	1.7 fold increase
AUC _{last}	Similar to control	1.6 fold increase	2.8 fold increase
NALOXONE			
C _{max}	Similar to control	2.7 fold increase	11.3 fold increase
AUC _{last}	0.2 fold decrease	3.2 fold increase	14 fold increase

In the same study, changes in C_{max} and AUC_{last} of buprenorphine and naloxone in subjects with HCV infection without hepatic impairment were not clinically significant in comparison to the healthy subjects.

Use in renal impairment

Renal elimination plays a relatively small role (~30%) in the overall clearance of buprenorphine. Therefore, no dose modification based on renal function is generally required. Metabolites of buprenorphine accumulate in patients with renal failure. Caution is recommended when dosing patients with severe renal impairment (CL_{cr} <30 mL/min), which may require dose adjustment.

Head Injury and Increased Intracranial Pressure

SUBOXONE FILM, like other potent opioids may itself elevate cerebrospinal fluid pressure, which may cause seizures, and should be used with caution in patients with head injury, intracranial lesions and other circumstances where cerebrospinal pressure may be increased, or history of seizure. SUBOXONE FILM can produce miosis and changes in the level of consciousness, or changes in the perception of pain as a symptom of disease and may interfere with patient evaluation or obscure the diagnosis or clinical course of concomitant disease.

Opioid Withdrawal Effects

Because SUBOXONE FILM contains naloxone, it is highly likely to produce marked and intense opioid withdrawal symptoms if injected by patients treated with SUBUTEX or SUBOXONE or by persons dependent on full opioid agonists such as heroin, oxycodone, morphine or methadone.

SUBOXONE FILM may produce withdrawal symptoms in opioid dependent subjects if it is administered too soon after another opioid. Discontinuation of treatment may result in a withdrawal syndrome that may be delayed.

Buprenorphine is a partial agonist at the μ (mu)-opiate receptor and studies in animals, as well as clinical experience, have shown that buprenorphine may produce dependence, but at a lower level than morphine. Consequently, it is important to follow the recommendations in section 4.2 Dose and Method of administration. Withdrawal symptoms may also be associated with suboptimal dosing.

Neonatal Abstinence Syndrome

Chronic use of buprenorphine by the mother at the end of pregnancy may result in a withdrawal syndrome (e.g. hypertonia, neonatal tremor, neonatal agitation, myoclonus, apnoea, convulsions or bradycardia) in the neonate. In many reported cases the withdrawal was serious and required treatment. The syndrome is generally delayed for several hours to several days after birth (see section 4.6 Use in Pregnancy). Due to the long half-life of buprenorphine, neonatal monitoring for several days should be considered to prevent the risk of respiratory depression or withdrawal

syndrome in neonates.

Allergic Reactions

Cases of acute and chronic hypersensitivity to buprenorphine have been reported both in clinical trials and in the post-marketing experience. The most common signs and symptoms include rashes, hives and pruritus. Cases of bronchospasm, angioneurotic oedema and anaphylactic shock have been reported. A history of hypersensitivity to buprenorphine or naloxone is a contraindication to SUBOXONE FILM use.

Paediatric Use

SUBOXONE FILM is not recommended for use in children. The safety and effectiveness of SUBOXONE FILM in subjects below the age of 16 has not been established. Due to limited amount of available data, patients between 16 and 18 years of age should be closely monitored during treatment.

Effects on Laboratory Tests

Athletes should be aware that this medicine may cause a positive reaction to “anti-doping” tests.

Use in Opioid Naïve Patients

There have been reported deaths of opioid naïve individuals who received doses as low as 2 mg of buprenorphine sublingual tablet for analgesia. SUBOXONE is not appropriate as an analgesic.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Alcohol

Alcohol increases the sedative effect of buprenorphine/naloxone. SUBOXONE should not be used together with alcoholic drinks and must be used cautiously with medicines containing alcohol (see section 4.4 Special Warnings and Precautions for Use).

Benzodiazepines

This combination may result in death due to respiratory depression of central origin; therefore, patients must be closely monitored when prescribed this combination and this combination should be avoided where there is a risk of misuse. Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines while taking this product and should also be cautioned to use benzodiazepines concurrently with this product only as prescribed (see section 4.4 Special Warnings and Precautions for Use).

Other central nervous system depressants

Combining central nervous system depressants with buprenorphine increases central nervous system depressant effects. The reduced level of alertness can make driving and using machinery dangerous. Examples include opioids (e.g. methadone, analgesics and antitussives), certain antidepressants, sedative H1-receptor antagonists, barbiturates, anxiolytics, neuroleptics, clonidine (see section 4.4 Special Warnings and Precautions for Use).

Opioid analgesics

The analgesic properties of other opioids such as methadone and level III analgesics may be reduced in patients receiving treatment with buprenorphine/naloxone for opioid dependence. Adequate analgesia may be difficult to achieve when administering a full opioid agonist in patients receiving SUBOXONE. Conversely, the potential for overdose should be considered with higher than usual doses of full agonist opioids, such as methadone or level III analgesics, especially when attempting to overcome buprenorphine partial agonist effects, or when buprenorphine plasma levels are declining. Patients with a need for analgesia and opioid dependence treatment may be best managed by multidisciplinary teams that include both pain and opioid dependence treatment specialists (see section 4.4 Special Warnings and Precautions for Use).

Naltrexone and other opioid antagonists

Since buprenorphine is a partial mu-opioid agonist, concomitantly administered opioid antagonists such as naltrexone can reduce or completely block the effects of SUBOXONE FILM. Patients maintained on SUBOXONE FILM may experience a sudden onset of prolonged and intense opioid withdrawal symptoms if dosed with opioid antagonists that achieve pharmacologically relevant systemic concentrations.

CYP3A4 inhibitors

An interaction study of buprenorphine with ketoconazole (a potent inhibitor of CYP3A4) resulted in increased C_{max} and AUC of buprenorphine (approximately 50% and 70% respectively) and, to a lesser extent, of norbuprenorphine. Patients receiving SUBOXONE FILM should be closely monitored and may require dose reduction if combined with potent CYP3A4 inhibitors e.g. protease inhibitors like ritonavir, nelfinavir or indinavir, azole antifungals like ketoconazole or itraconazole, calcium channel antagonists and macrolide antibiotics.

CYP3A4 inducers

Concomitant use of CYP3A4 inducers with buprenorphine may decrease buprenorphine plasma concentrations, potentially resulting in under-treatment of opioid dependence with buprenorphine; therefore, it is recommended that patients receiving SUBOXONE FILM should be closely monitored if inducers (e.g. phenobarbital, carbamazepine, phenytoin and rifampicin) are co-administered.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on Fertility

There were no effects on mating performance or fertility in rats following buprenorphine treatment at oral doses 20 times the maximum clinical dose of 32 mg/day (based on mg/m²). Dietary administration of SUBOXONE TABLETS to rats at doses of 47 mg/kg/day or greater (estimated respective buprenorphine and naloxone exposures 14 and 24 times the anticipated clinical exposure, based on plasma AUC) resulted in reduced female conception rates. A dietary dose of 9.4 mg/kg/day (twice the anticipated clinical exposure for both buprenorphine (based on AUC) and naloxone (based on mg/m²) had no adverse effect on fertility.

Use in Pregnancy – Pregnancy Category C

In rats, oral administration of buprenorphine at doses up to 20 times the maximum clinical dose of 32 mg/day (based on mg/m²) prior to and during gestation and lactation resulted in reduced implantation, fewer live births and reduced pup weight gain and survival. There was no evidence of teratogenicity in rats and rabbits following parenteral administration of buprenorphine during the period of organogenesis, although there was embryofoetal toxicity and reduced pup viability and developmental delays in rats. There was no evidence of teratogenicity in rats and rabbits following oral or intramuscular administration of maternally toxic doses of combinations of buprenorphine + naloxone during the period of organogenesis, although post-implantation losses were increased. In rats, oral (20 times maximum clinical dose, based on mg/m²) or intramuscular administration of buprenorphine from late gestation to weaning was associated with increased stillbirths, reduced postnatal survival and delayed postnatal development including weight gain and some neurological functions (surface righting reflex and startle response).

Buprenorphine readily crosses the placental barrier and may cause respiratory depression in neonates. During the last three months of pregnancy, chronic use of buprenorphine may be responsible for a withdrawal syndrome in neonates. SUBOXONE FILM should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Continued use of heroin during pregnancy is associated with significant risk to the mother and the foetus and neonate.

Data on the use of buprenorphine in pregnancy, and its impact on the mother and foetus, are limited. Data from randomised, controlled trials and observational studies do not indicate an increased risk of maternal or foetal adverse outcomes compared to methadone.

Use in Lactation

Animal studies indicate buprenorphine has the potential to inhibit lactation or milk production. In rats, oral (20 times maximum clinical dose, based on mg/m²) or intramuscular administration of buprenorphine from late gestation to weaning was associated with increased stillbirths, reduced postnatal survival and delayed postnatal development including weight gain and some neurological functions (surface righting reflex and startle response). The no effect level for developmental effects was twice the maximum clinical dose, based on mg/m². In two studies of thirteen women, buprenorphine was found in low levels in human breast milk. In both studies the estimated infant dose was <1% of the maternal dose. Because buprenorphine is excreted into human milk, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SUBOXONE FILM and any potential adverse effects on the breastfed child from the treatment or the underlying maternal condition.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

SUBOXONE may influence the ability to drive and use machinery when administered to opioid dependent patients. This product may cause drowsiness, dizziness, or impaired thinking, especially during treatment induction and dose adjustment. If used together with alcohol or central nervous system depressants, the effect is likely to be more pronounced (see section 4.4 Special Warnings and Precautions for Use and section 4.5 Interactions). Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that SUBOXONE therapy does not adversely affect their ability to engage in such activities.

4.8 UNDESIRABLE EFFECTS

Safety Study of SUBOXONE FILM

The clinical safety of SUBOXONE FILM was evaluated in a trial (RB-US-07-0001) of 382 patients stabilised on SUBOXONE TABLETS for at least 30 days and then switched to SUBOXONE FILM for maintenance treatment. Two hundred and forty-nine (249) patients completed at least 12 weeks of dosing with the SUBOXONE FILM. Patients received SUBOXONE FILM sublingually or buccally in a 1:1 ratio (N=194 sublingually, N=188 buccally). Adjunctive treatment was "treatment as usual" with varying levels of counselling and behavioural treatment. Treatment was conducted on an outpatient basis. Among all patients who received SUBOXONE FILM either sublingually or buccally, the most common treatment emergent adverse events were oral mucosal erythema, sinusitis, nausea, toothache, pain and upper respiratory tract infection. The most common treatment emergent adverse event for the patients administered SUBOXONE FILM sublingually was upper respiratory tract infection (4 patients, 2.1%) and for patients administered SUBOXONE FILM buccally were oral mucosal erythema (6 patients, 3.2%), nausea (4 patients, 2.1%) and sinusitis (4 patients, 2.1%). All other adverse events were reported in 3 (1.5% or 1.6%, respectively) or fewer patients.

Adverse events reported to occur to at least 1% of patients being treated with SUBOXONE FILM in this trial are shown in Table 3.

Table 3 Adverse Events (≥1%) by Body System and Treatment Group in Study RB-US-07-0001, Sublingual and Buccal Administration

System Organ Class Preferred term	Sublingual N=194	Buccal N=188
Infections and Infestations		
Sinusitis	3 (1.5%)	4 (2.1%)
Upper respiratory tract infection	4 (2.1%)	2 (1.1%)
Pharyngitis streptococcal	2 (1.0%)	2 (1.1%)
Urinary tract infection	3 (1.5%)	1 (0.5%)
Influenza	2 (1.0%)	1 (0.5%)
Tooth abscess	2 (1.0%)	0 (0%)
Nasopharyngitis	0 (0%)	3 (1.6%)
Cellulitis	0 (0%)	2 (1.1%)
Gastrointestinal Disorders		
Glossodynia	3 (1.5%)	1 (0.5%)
Hypoaesthesia oral	2 (1.0%)	1 (0.5%)
Nausea	3 (1.5%)	3 (1.6%)
Oral mucosal erythema	2 (1.0%)	6 (3.2%)
Toothache	2 (1.0%)	4 (2.1%)
Vomiting	3 (1.5%)	2 (1.1%)
Gastroesophageal reflux disease	1 (0.5%)	3 (1.6%)
Constipation	1 (0.5%)	2 (1.1%)
Musculoskeletal and Connective Tissues Disorders		
Back pain	3 (1.5%)	1 (0.5%)
Arthralgia	2 (1.0%)	0 (0%)
Musculoskeletal pain	2 (1.0%)	0 (0%)
Muscle spasms	0 (0%)	2 (1.1%)
Psychiatric Disorders+		
Stress	2 (1.0%)	1 (0.5%)
Drug dependence (craving)	0 (0%)	2 (1.1%)
Injury, Poisoning and Procedural Complications		
Skin laceration	2 (1.0%)	1 (0.5%)
Road traffic accident	0 (0%)	2 (1.1%)
General Disorders and Administration Site Conditions		
Pain	3 (1.5%)	3 (1.6%)
Oedema peripheral	1 (0.5%)	2 (1.1%)
Nervous System Disorders		
Headache	2 (1.0%)	3 (1.6%)
Migraine	1 (0.5%)	2 (1.1%)

System Organ Class Preferred term	Sublingual N=194	Buccal N=188
Renal and Urinary Disorders		
Nephrolithiasis	2 (1.0%)	2 (1.1%)
Metabolism and Nutrition Disorders		
Gout	1 (0.5%)	2 (1.1%)
Respiratory, Thoracic and Mediastinal Disorders		
Cough	0 (0%)	2 (1.1%)
Skin and Subcutaneous Tissue Disorders		
Dermatitis contact	2 (1.0%)	0 (0%)
Pregnancy, Puerperium and Perinatal Conditions		
Pregnancy	2 (1.0%)	0 (0%)

* AEs are coded using Medical Dictionary for Regulatory Activities (MedDRA) version 11.0 terminology.

Clinical trials of SUBOXONE TABLETS

Adverse events reported to occur to at least 1% of patients being treated in clinical trials of SUBOXONE TABLETS (CR96/013 + CR96/014) are shown in Tables 4 and 5.

Table 4. Adverse Events (≥1%) by Body System and Treatment Group in Study CR96/013

Body System/ Adverse Event (COSTART Terminology)	SUBOXONE (buprenorphine/naloxone) TABLETS 16/4 mg/day N=107 n (%)	SUBUTEX (buprenorphine) TABLETS 16 mg/day N=103 n (%)	Placebo N=107 n (%)	All Subjects (N = 317) n (%)
Body as a Whole				
Abscess	2 (1.9%)	1 (1.0%)	1 (0.9%)	4 (1.3%)
Asthenia	7 (6.5%)	5 (4.9%)	7 (6.5%)	19 (6.0%)
Chills	8 (7.5%)	8 (7.8%)	8 (7.5%)	24 (7.6%)
Fever	3 (2.8%)	3 (2.9%)	4 (3.7%)	10 (3.2%)
Headache	39 (36.4%)	30 (29.1%)	24 (22.4%)	93 (29.3%)
Infection	6 (5.6%)	12 (11.7%)	7 (6.5%)	25 (7.9%)
Accidental Injury	2 (1.9%)	5 (4.9%)	5 (4.7%)	12 (3.8%)
Pain	24 (22.4%)	19 (18.4%)	20 (18.7%)	63 (19.9%)
Pain abdomen	12 (11.2%)	12 (11.7%)	7 (6.5%)	31 (9.8%)
Pain back	4 (3.7%)	8 (7.8%)	12 (11.2%)	24 (7.6%)
Withdrawal syndrome	27 (25.2%)	19 (18.4%)	40 (37.4%)	86 (27.1%)
Cardiovascular System				
Vasodilation	10 (9.3%)	4 (3.9%)	7 (6.5%)	21 (6.6%)

Body System/ Adverse Event (COSTART Terminology)	SUBOXONE (buprenorphine/naloxone) TABLETS 16/4 mg/day N=107 n (%)	SUBUTEX (buprenorphine) TABLETS 16 mg/day N=103 n (%)	Placebo N=107 n (%)	All Subjects (N = 317) n (%)
Digestive System				
Constipation	13 (12.1%)	8 (7.8%)	3 (2.8%)	24 (7.6%)
Diarrhea	4 (3.7%)	5 (4.9%)	16 (15.0%)	25 (7.9%)
Dyspepsia	4 (3.7%)	5 (4.9%)	5 (4.7%)	14 (4.4%)
Nausea	16 (15.0%)	14 (13.6%)	12 (11.2%)	42 (13.2%)
Vomiting	8 (7.5%)	8 (7.8%)	5 (4.7%)	21 (6.6%)
Metabolic/Nutritional Disorders				
Peripheral Edema	1 (0.9%)	1 (1.0%)	2 (1.9%)	4 (1.3%)
Musculoskeletal System				
Myalgia	4 (3.7%)	1 (1.0%)	1 (0.9%)	6 (1.9%)
Nervous System				
Agitation	3 (2.8%)	2 (1.9%)	0	5 (1.6%)
Anxiety	3 (2.8%)	5 (4.9%)	4 (3.7%)	12 (3.8%)
Dizziness	5 (4.7%)	3 (2.9%)	4 (3.7%)	12 (3.8%)
Hyperkinesia	3 (2.8%)	2 (1.9%)	0	5 (1.6%)
Hypertonia	2 (1.9%)	0	2 (1.9%)	4 (1.3%)
Insomnia	15 (14.0%)	22 (21.4%)	17 (15.9%)	54 (17.0%)
Nervousness	5 (4.7%)	6 (5.8%)	4 (3.7%)	15 (4.7%)
Paresthesia	3 (2.8%)	3 (2.9%)	0	6 (1.9%)
Somnolence	8 (7.5%)	4 (3.9%)	2 (1.9%)	14 (4.4%)
Thinking Abnormal	2 (1.9%)	1 (1.0%)	1 (0.9%)	4 (1.3%)
Tremor	2 (1.9%)	1 (1.0%)	2 (1.9%)	5 (1.6%)
Respiratory System				
Cough Increased	1 (0.9%)	2 (1.9%)	2 (1.9%)	5 (1.6%)
Pharyngitis	2 (1.9%)	4 (3.9%)	1 (0.9%)	7 (2.2%)
Rhinitis	5 (4.7%)	10 (9.7%)	14 (13.1%)	29 (9.1%)
Skin And Appendages				
Sweating	15 (14.0%)	13 (12.6%)	11 (10.3%)	39 (12.3%)
Special Senses				
Amblyopia	3 (2.8%)	1 (1.0%)	0	4 (1.3%)
Lacrimation Disorder	0	4 (3.9%)	6 (5.6%)	10 (3.2%)

Body System/ Adverse Event (COSTART Terminology)	SUBOXONE (buprenorphine/naloxone) TABLETS 16/4 mg/day N=107 n (%)	SUBUTEX (buprenorphine) TABLETS 16 mg/day N=103 n (%)	Placebo N=107 n (%)	All Subjects (N = 317) n (%)
Urogenital System				
Dysmenorrhea	2 (1.9%)	1 (1.0%)	2 (1.9%)	5 (1.6%)
Urinary Tract Infection	1 (0.9%)	1 (1.0%)	2 (1.9%)	4 (1.3%)

Abbreviations: COSTART = Coding Symbols for Thesaurus of Adverse Reaction Terms.

Table 5. Adverse Events (≥1%) by Body System and Treatment Group in Study CR96/014

Body System/ Adverse Event (COSTART Terminology)	All SUBOXONE TABLET Subjects N=472 n (%)	Body System/ Adverse Event (COSTART Terminology)	All SUBOXONE TABLET Subjects N=472 n (%)
Body as a Whole		Liver Function Abnormal	18 (3.8%)
Abscess	17 (3.6%)	Nausea	76 (16.1%)
Allergic Reaction	8 (1.7%)	Stomatitis	5 (1.1%)
Asthenia	48 (10.2%)	Tooth Disorder	37 (7.8%)
Chills	44 (9.3%)	Ulcer, Mouth	6 (1.3%)
Cyst	7 (1.5%)	Vomiting	61 (12.9%)
Edema, Face	8 (1.7%)	Hemic/Lymphatic System	
Fever	36 (7.6%)	Anemia	7 (1.5%)
Flu Syndrome	89 (18.9%)	Ecchymosis	6 (1.3%)
Headache	202 (42.8%)	Lymphadenopathy	5 (1.1%)
Infection	5 (1.1%)	Metabolic/Nutritional Disorders	
Infection, Viral	5 (1.1%)	Peripheral Edema	24 (5.1%)
Accidental Injury	72 (15.3%)	Hyperglycemia	5 (1.1%)
Malaise	9 (1.9%)	Weight Decreased	15 (3.2%)
Neck Rigid	5 (1.1%)	Musculoskeletal System	
Pain	197 (41.7%)	Arthralgia	20 (4.2%)
Pain, Abdomen	77 (16.3%)	Arthritis	5 (1.1%)
Pain, Back	132 (28.0%)	Leg Cramps	13 (2.8%)
Pain, Chest	23 (4.9%)	Joint Disorder	9 (1.9%)
Pain, Neck	12 (2.5%)	Myalgia	31 (6.6%)
Withdrawal Syndrome	194 (41.1%)	Nervous System	
Cardiovascular System		Agitation	10 (2.1%)
Hypertension	17 (3.6%)	Anxiety	65 (13.8%)
Migraine	13 (2.8%)	Depression	70 (14.8%)
Vasodilation	29 (6.1%)	Dizziness	33 (7.0%)
Digestive System		Dream Abnormalities	9 (1.9%)
Abscess, Periodontal	10 (2.1%)	Drug Dependence	9 (1.9%)
Anorexia	16 (3.4%)	Hypertonia	9 (1.9%)
Constipation	115 (24.4%)	Insomnia	138 (29.2%)
Diarrhea	50 (10.6%)	Libido Decreased	9 (1.9%)
Dyspepsia	45 (9.5%)	Nervousness	42 (8.9%)
Flatulence	11 (2.3%)	Paresthesia	28 (5.9%)
Gastrointestinal Disorder		Somnolence	40 (8.5%)

Body System/ Adverse Event (COSTART Terminology)	All SUBOXONE TABLET Subjects N=472 n (%)	Body System/ Adverse Event (COSTART Terminology)	All SUBOXONE TABLET Subjects N=472 n (%)
Thinking Abnormal	6 (1.3%)	Nodule, Skin	6 (1.3%)
Tremor	7 (1.5%)	Pruritus	11 (2.3%)
Respiratory System		Skin Dry	6 (1.3%)
Asthma	21 (4.4%)	Sweat	74 (15.7%)
Bronchitis	9 (1.9%)	Urticaria	6 (1.3%)
Cough Increased	36 (7.6%)	Special Senses	
Dyspnea	9 (1.9%)	Amblyopia	5 (1.1%)
Lung Disorder	10 (2.1%)	Conjunctivitis	14 (3.0%)
Pharyngitis	64 (13.6%)	Eye Disorder	8 (1.7%)
Pneumonia	12 (2.5%)	Lacrimation Disorder	14 (3.0%)
Respiratory Disorder	7 (1.5%)	Pain, Ear	8 (1.7%)
Rhinitis	75 (15.9%)	Urogenital System	
Sinusitis	7 (1.5%)	Dysmenorrhea	19 (4.0%)
Sputum Increased	5 (1.1%)	Dysuria	9 (1.9%)
Yawn	6 (1.3%)	Hematuria	8 (1.7%)
Skin and Appendages		Impotence	11 (2.3%)
Acne	5 (1.1%)	Urinary Tract Infection	19 (4.0%)
Dermatological Contact	5 (1.1%)	Urine Abnormality	12 (2.5%)
Herpes Simplex	6 (1.3%)	Vaginitis	11 (2.3%)

The most common ($\geq 10\%$) adverse events reported were those related to withdrawal symptoms (e.g. insomnia, headache, constipation, nausea, abdominal pain, diarrhoea, muscle aches, anxiety, sweating). In patients with marked opioid dependence, initial administration of buprenorphine can produce a withdrawal effect similar to that associated with naloxone.

Note - Patients enrolled in study RB-US-07-0001 on the soluble film were on a stable buprenorphine treatment prior to study initiation, while patients enrolled in studies CR96/013 and CR96/014 were buprenorphine-naïve individuals. As a result, the number of AEs observed in study RB-US-07-0001 is likely to be lower than that observed in studies CR96/013 and CR96/014.

Post-marketing experience with buprenorphine alone

Post-marketing experience with buprenorphine alone has been associated with the following side effects: respiratory depression (see section 4.4 Special Warnings and Precautions for Use) and coma, hallucinations, neonatal withdrawal syndrome, neonatal tremor, neonatal feeding disorder, foetal disorders, convulsions, confusion, miosis, weight decrease, asphyxia, hypoventilation, urinary retention, vertigo, drug dependence, headache, nausea, vomiting, drug withdrawal syndrome, peripheral oedema, heart rate and rhythm disorders and deaths.

Cases of hepatitis, jaundice, hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic encephalopathy and elevations in hepatic transaminases have been reported with buprenorphine use (see section 4.4 Special Warnings and Precautions for Use).

In cases of intravenous misuse of buprenorphine, local reactions, sometimes septic, potentially serious acute hepatitis, pneumonia, endocarditis and other serious infections have been reported.

Cases of acute or chronic hypersensitivity have been reported with buprenorphine with symptoms including rashes, hives, pruritus and reported cases of bronchospasm, angioneurotic oedema and anaphylactic shock (see section 4.4 Special Warnings and Precautions for Use and section 4.3 Contraindications).

Very rare (<0.01%) side effects: loss of consciousness, cognitive disorders, psychosis, hallucinations, suicidal ideation, disorders of pregnancy (such as miscarriage and termination of pregnancy, premature birth, placental abruption, prolonged labour), foetal and neonatal complications (such as foetal disorders, foetal malformation, foetal growth retardation, foetal cystic hygroma, micrognathia, decreased oxygen saturation, developmental speech disorder, foetal dwarfism, foetal asphyxia, foetal cardiac rhythm disorder, cleft palate, Klinefelter's Syndrome, intersexual genitalia, neonatal withdrawal syndrome, neonatal tremor, neonatal feeding disorder, infant respiratory distress syndrome and subarachnoid bleeding), heart murmur, convulsions, confusion, miosis, weight decrease, asphyxia, hypoventilation, pruritus, angioedema, heart rate and rhythm disorders, pulmonary oedema, septic shock, infections (including sepsis, septic arthritis and septic embolus, staphylococcal sacroileitis, brain abscess, pneumonia and endocarditis and amniotic fluid infection) events associated with intravenous misuse (such as cutaneous ulceration, eschar, lividoid and necrotic lesions and penile and scrotal lesion), aphasia, aphonia, slurred speech, diplopia, facial palsy, ascites and lymphoedema, pulmonary oedema, pulmonary artery thrombosis, pericardial effusion, shock, cerebrovascular accident, Popeye syndrome, intracranial haemorrhage, nephropathy, colic, denutrition splenic infarction, electrolyte imbalance (such as hyperkalaemia, hyponatraemia and hypoglycaemia), deaths (including death from suicide and sudden infant death syndrome) and unusual reactions. The actual incidence of all cases is extremely low and must be taken in consideration with the co-morbidities, life-style, environmental factors and concomitant illicit and licit opioid use of the population under treatment.

Post-marketing experience with SUBOXONE TABLETS

A post-marketing study looking at injecting practices in Australia suggested that the combination of buprenorphine and naloxone is less commonly injected than buprenorphine alone.

Additionally, post-marketing experience with SUBOXONE TABLETS for treatment of opioid dependence has been associated with the following side effects: anxiety, hyperhidrosis, syncope, insomnia, reduced feeling, anorexia (see also Tables 4 and 5 above), amnesia, convulsions, blood in vomit, fatigue, jaundice, swollen joints, miscarriage, shortness of breath and suicide ideation. Treatment with SUBOXONE has been associated with orthostatic hypotension.

Additionally, post-marketing experience with SUBOXONE TABLETS for treatment of opioid dependence has been associated very rarely (<0.01%) with the following side effects: attempted suicide, disorders of pregnancy (such as premature birth), foetal and neonatal complications (such as foetal disorders, foetal malformation, foetal growth retardation, foetal cystic hygroma, micrognathia, macrocephaly, meconium staining and aspiration, decreased oxygen saturation, neonatal aspiration, asphyxia, developmental speech disorder, foetal dwarfism, foetal asphyxia, foetal cardiac rhythm disorder, low birth weight, Klinefelter's Syndrome, mitochondrial disease, abnormal behaviour, developmental delay, developmental speech disorder intersexual genitalia, neonatal withdrawal syndrome, neonatal tremor, neonatal feeding disorder, subarachnoid bleeding and sudden infant death syndrome), pancreatitis, loss of consciousness, depression of consciousness, coordination disturbance, hallucinations, psychosis, mental disturbance and altered mental state, cerebral oedema, heart rate and rhythm disorders, septic shock, infections (including sepsis, pneumonia, chorioamnionitis and amniotic fluid infection) events associated with intravenous misuse (such as cellulitis), blurred vision, papilloedema, ascites and peripheral oedema, renal failure, adrenal insufficiency, electrolyte imbalance (such as hyperkalaemia, hypocalcaemia, hypomagnesaemia, hyponatraemia and hypoglycaemia) and deaths (including death from suicide and sudden infant death syndrome). The actual incidence of all cases is extremely low and must be taken in consideration with the co-morbidities, life-style, environmental factors and concomitant illicit and licit opioid use of the population under treatment.

Post-marketing experience with SUBOXONE FILM

Post-marketing experience with SUBOXONE FILM for the treatment of opioid dependence has been most frequently associated with the following; adverse reactions appearing in at least 1% of reports by healthcare professionals are included in Table 6.

System Organ Class	Preferred term
<i>Nervous system disorders</i>	Headache
<i>Gastrointestinal disorders</i>	Glossitis Nausea Stomatitis Tongue disorder Vomiting
<i>Skin and subcutaneous disorders</i>	Rash
<i>General disorders and administration site conditions</i>	Drug ineffective Drug withdrawal syndrome Oedema peripheral

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

For adverse event reporting please contact:

Indivior Pty Ltd

+800-270-81901

PatientSafetyRoW@indivior.com

4.9 OVERDOSE

Manifestations of acute overdose include miosis, sedation, hypotension, respiratory depression and death. Nausea and vomiting may be observed.

The major symptom requiring intervention is respiratory depression, which could lead to respiratory arrest and death. If the patient vomits, care must be taken to prevent aspiration of the vomitus.

Treatment

In the event of depression of respiratory or cardiac function, primary attention should be given to the re-establishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation following standard intensive care measures. The patient should be transferred to an environment within which full resuscitation facilities are available.

Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated. High doses of naloxone hydrochloride 10-35 mg/70 kg may be of limited value in the management of buprenorphine overdose.

The long duration of action of SUBOXONE FILM should be taken into consideration when determining the length of treatment needed to reverse the effects of an overdose. Naloxone can be cleared more rapidly than buprenorphine, allowing for a return of previously controlled buprenorphine overdose symptoms, so a continuing infusion may be necessary. Ongoing IV infusion rates should be titrated to patient response. If infusion is not possible, repeated dosing with naloxone may be required.

For advice on the management of overdose, please contact the National Poisons Centre on 0800 POISON (0800 764 766).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Other nervous system drugs, drugs used in addictive disorders, ATC code: N07BC51.

Mechanism of action

Buprenorphine is a μ (μ) opioid receptor partial agonist, κ (κ) opioid receptor antagonist. Its activity in opioid maintenance treatment is attributed to its slow dissociation from the μ receptors in the brain which reduces craving for opioids and opioid withdrawal symptoms. This minimises the need of the opioid dependent patient for illicit opioid medicines.

During clinical pharmacology studies in opioid dependent subjects, buprenorphine demonstrated a ceiling effect on a number of parameters, including positive mood, "good effect" and respiratory depression.

Naloxone is an antagonist at μ (μ), δ (δ) and κ (κ) opioid receptors. Because of its almost complete first pass metabolism, naloxone administered orally, sublingually or buccally has no detectable pharmacological activity. However, when administered intravenously to opioid dependent persons, the presence of naloxone in SUBOXONE FILM produces marked opioid antagonist effects and opioid withdrawal, thereby deterring intravenous abuse.

Clinical Trials

Efficacy of buprenorphine in combination with naloxone was demonstrated with SUBOXONE TABLETS. No clinical efficacy studies have been conducted with SUBOXONE FILM.

All trials used buprenorphine in conjunction with psychosocial counselling as part of a comprehensive opioid dependence treatment program. There have been no clinical studies conducted to assess the efficacy of buprenorphine as the only component of treatment.

Clinical pharmacology studies on SUBOXONE TABLETS demonstrate an aversive effect if SUBOXONE TABLETS are misused by the injection route by opioid dependent patients.

5.2 PHARMACOKINETIC PROPERTIES

Absorption

When taken orally, buprenorphine undergoes first-pass metabolism with N-dealkylation and glucuronidation in the small intestine and the liver. The use of SUBOXONE FILM by the oral route is therefore inappropriate. SUBOXONE FILMS are for sublingual and/or buccal administration. Table 7 shows the pharmacokinetic parameters of buprenorphine, norbuprenorphine and naloxone after administration of SUBOXONE FILM in randomised, crossover studies. Overall, there was wide variability in the sublingual absorption of buprenorphine and naloxone. SUBOXONE FILM and SUBOXONE TABLET do not meet all criteria for bioequivalence. Patients being switched between tablets and soluble films may therefore require dosage adjustment (see Dosage and Administration).

In several pharmacokinetic studies following the administration of different dosages, a dose of one or two of the 2 mg/0.5 mg SUBOXONE FILMS administered sublingually or buccally showed comparable relative bioavailability to the same total dose of SUBOXONE TABLETS. In contrast, one 8 mg/2 mg and one 12 mg/3 mg SUBOXONE FILM administered sublingually or buccally showed higher relative bioavailability for both buprenorphine and naloxone compared to the same total dose of SUBOXONE TABLETS. A combination of one 8 mg/2 mg and two 2 mg/0.5 mg

SUBOXONE FILMS (total dose of 12 mg/ 3 mg) administered sublingually showed comparable relative bioavailability to the same total dose of SUBOXONE TABLETS, while buccally administered SUBOXONE FILMS showed higher relative bioavailability. Table 8 below illustrates the relative increase in exposure to buprenorphine and naloxone associated with SUBOXONE FILMS compared to SUBOXONE TABLETS and shows the effect of route of administration.

Table 7. Pharmacokinetic parameters (Mean ± SD) of buprenorphine and naloxone following SUBOXONE FILM administration				
PK Parameter	SUBOXONE Film Dose (mg)			
	2 mg/0.5 mg	4 mg / 1 mg	8 mg / 2 mg	12 mg / 3 mg
Buprenorphine				
C _{max} (ng/mL)	0.947 ± 0.374	1.40 ± 0.687	3.37 ± 1.80	4.55 ± 2.50
T _{max} (h) Median, (min-max)	1.53 (0.75 - 4.0)	1.50 (0.5, 3.0)	1.25 (0.75 - 4.0)	1.50 (0.5, 3.0)
AUC _{inf} (ng.hr/mL)	8.654 ± 2.854	13.71 ± 5.875	30.45 ± 13.03	42.06 ± 14.64
t _{1/2} (hr)	33.41 ± 13.01	24.30 ± 11.03	32.82 ± 9.81	34.66 ± 9.16
Norbuprenorphine				
C _{max} (ng/mL)	0.312 ± 0.140	0.617 ± 0.311	1.40 ± 1.08	2.37 ± 1.87
T _{max} (h) Median, (min-max)	1.38 (0.5 - 8.0)	1.25 (0.5, 48.0)	1.25 (0.75 - 12.0)	1.25 (0.75, 8.0)
AUC _{inf} (ng.hr/mL)	14.52 ± 5.776	23.73 ± 10.60	54.91 ± 36.01	71.77 ± 29.38
t _{1/2} (hr)	56.09 ± 31.14	45.96 ± 40.13	41.96 ± 17.92	34.36 ± 7.92
Naloxone				
C _{max} (ng/mL)	0.054 ± 0.023	0.0698 ± 0.0378	0.193 ± 0.091	0.238 ± 0.144
T _{max} (h) Median, (min-max)	0.75 (0.5 - 2.0)	0.75 (0.5, 1.5)	0.75 (0.5 - 1.25)	0.75 (0.50, 1.25)
AUC _{inf} (ng.hr/mL)	0.137 ± 0.043	0.204 ± 0.108	0.481 ± 0.201	0.653 ± 0.309
t _{1/2} (hr)	5.00 ± 5.52	3.91 ± 3.37	6.25 ± 3.14	11.91 ± 13.80

Table 8. Changes in Pharmacokinetic Parameters for SUBOXONE FILM Administered Sublingually or Buccally in Comparison to SUBOXONE TABLET								
Dosage	PK Parameter	Increase in Buprenorphine			PK Parameter	Increase in Naloxone		
		Film Sublingual Compared to Tablet Sublingual	Film Buccal Compared to Tablet Sublingual	Film Buccal Compared to Film Sublingual		Film Sublingual Compared to Tablet Sublingual	Film Buccal Compared to Tablet Sublingual	Film Buccal Compared to Film Sublingual
1 x 2 mg/0.5 mg	C _{max}	22%	25%	-	C _{max}	-	-	-
	AUC _{0-last}	-	19%	-	AUC _{0-last}	-	-	-

2 x 2 mg/0.5 mg	C _{max}	-	21%	21%	C _{max}	-	17%	21%
	AUC _{0-last}	-	23%	16%	AUC _{0-last}	-	22%	24%
1 x 8 mg/2 mg	C _{max}	28%	34%	-	C _{max}	41%	54%	-
	AUC _{0-last}	20%	25%	-	AUC _{0-last}	30%	43%	-
1 x 12 mg/3 mg	C _{max}	37%	47%	-	C _{max}	57%	72%	9%
	AUC _{0-last}	21%	29%	-	AUC _{0-last}	45%	57%	-
1 x 8 mg/2 mg plus 2 x 2 mg/0.5 mg	C _{max}	-	27%	13%	C _{max}	17%	38%	19%
	AUC _{0-last}	-	23%	-	AUC _{0-last}	-	30%	19%

Note: 1. '-' represents no change when the 90% confidence intervals for the geometric mean ratios of the C_{max} and AUC_{0-last} values are within the 80% to 125% limit. 2. There is no data for the 4 mg/1 mg strength film; it is compositionally proportional to 2 mg/0.5 mg strength film and has the same size of 2 x 2 mg/0.5 mg film strength.

Distribution

The absorption of buprenorphine is followed by a rapid distribution phase (distribution half-life of 2 to 5 hours). Following intravenous administration, naloxone is rapidly distributed (distribution half-life of around 4 minutes).

Buprenorphine is highly lipophilic which leads to rapid penetration of the blood-brain barrier. The medicine is around 96% protein bound primarily to alpha and beta globulin. Naloxone is approximately 45% protein bound, primarily to albumin.

Metabolism

In animals and man buprenorphine is metabolised by Phase 1 (oxidative) and Phase 2 (conjugation) reactions. It is oxidatively metabolised by N-dealkylation to norbuprenorphine by CYP 3A4. In in vitro metabolic studies, addition of specific inhibitors of CYP 3A4 (e.g. ketoconazole, gestodene, nifedipine, norfluoxetine, ritonavir) inhibited formation of norbuprenorphine (see also section 4.4 Special Warnings and Precautions for Use and section 4.5 Interactions). There was no indication of the involvement of CYP 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 2E1 in the N-dealkylation of buprenorphine. Buprenorphine was a weak competitive inhibitor of CYP 2D6 and CYP 3A4. Norbuprenorphine is a μ (μ) agonist with weak intrinsic activity and is considered to be an inactive metabolite.

Naloxone undergoes direct glucuroconjugation to naloxone-3-glucuronide as well as N-dealkylation and reduction of the 6-oxo group.

Excretion

Elimination of buprenorphine is bi- or tri-exponential, with a long terminal elimination phase (refer to Table 1), due in part to re-absorption of buprenorphine after intestinal hydrolysis of the conjugated metabolite and in part to the highly lipophilic nature of the molecule. Naloxone has a short elimination half-life (refer to Table 7).

Buprenorphine is essentially eliminated in the faeces by biliary excretion of the glucuroconjugated metabolites (70%), the rest being eliminated in the urine. Naloxone is excreted in the urine.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

In genotoxicity studies using buprenorphine and naloxone (9:2), assays for bacterial gene mutations and chromosomal damage (human lymphocytes *in vitro* and rat micronucleus test *in vivo*) were negative.

Carcinogenicity

In mice, no evidence for carcinogenicity due to buprenorphine was noted in life-time studies at dietary doses of up to 100 mg/kg/day, which equates to ca 14-fold human exposure at the maximum recommended clinical dose of 32 mg based on body surface area.

In rats, statistically significant (trend test adjusted for survival) dose-related increases in testicular interstitial (Leydig) cell tumours occurred at a dietary buprenorphine dose of 55 mg/kg/day (16 fold the maximal recommended human sublingual dose of 32 mg, on a mg/m² basis); the no-effect dose was 5.4 mg/kg/day (twice the maximal human dose, on a mg/m² basis).

The carcinogenic potential of naloxone alone has not been investigated in long term animal studies.

In a 2-year dietary study with SUBOXONE TABLETS in rats, Leydig cell adenomas were found at doses of 6-115 mg/kg/day, associated with respective exposures (plasma AUC) to buprenorphine and naloxone of 2-21 fold, and up to 58 fold, anticipated human exposure. A NOEL was not established in the study.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Acesulfame potassium
Citric acid
Maltitol
Hypromellose
Polyethylene oxide
Sodium citrate
Natural Lime flavour 3000180
Sunset Yellow FCF
OPACODE WB monogramming ink NS-78-18007 White.

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

18 months.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C.

6.5 NATURE AND CONTENTS OF CONTAINER

Each soluble film is packed in an individual child resistant polyethylene terephthalate (PET)/low density polyethylene (LDPE)/aluminium/LDPE sachet. There are 28 sachets in a pack.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE

Controlled Drug C4

8 SPONSOR

Pharmacy Retailing (NZ) Ltd
t/a Healthcare Logistics
58 Richard Pearse Drive
Airport Oaks
Mangere
Auckland 2022
Telephone (09) 918 5100
Fax: (09) 918 5101

9 DATE OF FIRST APPROVAL

21 October 2021

10 DATE OF REVISION OF THE TEXT

December 2020

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information